HemaSphere
(Jun 2022)
P461: MYELOID KINOME INHIBITOR HM43239 OVERCOMES ACQUIRED RESISTANCE IN ACUTE MYELOID LEUKEMIA MODELS
- R. Bejar,
- S. J. Baek,
- N. Abbasi,
- A. Krasny,
- R. Sinha,
- H. Zhang,
- S. Howell,
- W. Rice
Affiliations
- R. Bejar
- 1 Aptose Biosciences Inc., San Diego, United States of America
- S. J. Baek
- 2 Hanmi Pharmaceutical Company, Seoul, South Korea
- N. Abbasi
- 1 Aptose Biosciences Inc., San Diego, United States of America
- A. Krasny
- 1 Aptose Biosciences Inc., San Diego, United States of America
- R. Sinha
- 1 Aptose Biosciences Inc., San Diego, United States of America
- H. Zhang
- 1 Aptose Biosciences Inc., San Diego, United States of America
- S. Howell
- 3 Moores Cancer Center, University of San Diego Health, San Diego, United States of America
- W. Rice
- 1 Aptose Biosciences Inc., San Diego, United States of America
- DOI
-
https://doi.org/10.1097/01.HS9.0000844732.04312.e8
- Journal volume & issue
-
Vol. 6
pp.
360
– 361
WeChat QR code